Comparison of Her-2 status in primary gastric cancer with the corresponding endoscopic biopsies and lymph node metastases
10.3969/j.issn.1000-8179.20131796
- VernacularTitle:胃癌原发灶与胃镜活检标本及淋巴结转移灶中Her-2状态的比较
- Author:
Chenxi WANG
;
Jun ZHANG
- Publication Type:Journal Article
- Keywords:
gastric cancer;
lymph node metastasis;
Her-2;
concordance;
immunohistochemistry;
fluorescence in situ hybridization
- From:
Chinese Journal of Clinical Oncology
2014;(3):184-188
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to validate the accuracy and validity of Her-2 assessment used for endoscopic biopsies and lymph node metastases by comparing these samples with the surgical materials obtained from the same patients. This study also aimed to analyze the relationship between primary tumor and clinicopathological characteristics of gastric cancer. Methods:Her-2 sta-tus was evaluated according to Gastric cancer Her-2 testing guidelines in 107 cases of gastric cancers with coupled endoscopic biopsies and surgical materials and in 76 cases of the corresponding lymph node metastases. Results were then compared and analyzed. Re-sults:The complete concordance of the Her-2 status of endoscopic biopsies and surgical samples (n=107) was noted in 86.9%of the cases. This result is consistent between the two different samples (Z=6.381 3, P<0.000 1). Primary gastric cancer and the corresponding lymph node metastases also displayed uniformity (Z=3.027 4, P=0.002 5). The positive rate of Her-2 was significantly associated with Lauren type, tumor histological grade, depth of invasion, lymph node metastasis, and TNM stage. Conclusion:A high concordance was observed between primary tumor and biopsy specimen (endoscopic biopsies and lymph node metastases), in which Her-2 status exhibit-ed a high predictive value. Her-2 status is correlated with invasion and cancer metastasis. Hence, the most appropriate criteria for Her-2 status assessment in lymph nodes should be considered to improve the Her-2 diagnosis system of gastric cancer.
